BioCryst (BCRX) Pharmaceuticals announced that Dr. Helen Thackray, chief research and development officer, CRDO, will leave the company September 1, 2025 and transition into an advisory role through the end of the year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst’s BCX17725: A Promising Step Forward in Treating Netherton Syndrome
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves
- BioCryst’s Orladeyo: Strong Market Outlook and Strategic Expansion Drive Buy Rating
- BioCryst Pharmaceuticals Reports Record Q2 2025 Results